Oncology Investigator Studies Program (MISP)
To advance science and improve patient care by supporting, through the provision of drug and/or total/partial funding, high-quality research that is initiated, designed, implemented and sponsored by external investigators. Results will be generated and properly disseminated in peer-reviewed publications.
Overview

Pembrolizumab Funding Review Cycle
Clinical trials and preclinical studies (efficacy primary endpoints) with funding or funding & drug support.

Pembrolizumab Quarterly Drug Only Review Cycle
Clinical trials (efficacy primary endpoints) with "drug only" support.

Pembrolizumab Oncology Translational Studies Program (OTSP)
Translational studies (translational primary endpoints)

Olaparib and Selumetinib Proposals
Due to the recent partnership with AstraZeneca, MSD will now be jointly evaluating Externally Sponsored Research (ESR) proposals with olaparib and selumetinib

 

MISP Oncology Contact Information
To learn more or to ask a question, please contact the appropriate MSD Business Development and Licensing contact for your region.